Clinical trials
Phase 1 clinical trials
Below are recruiting phase 1 clinical trials, each written for real people, not researchers. We’re tracking 285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07668999RecruitingPhase 1
Study of ZYG24004 for athlete's foot caused by fungus
This trial tests a new medication called ZYG24004 for athlete's foot (tinea pedis) caused by specific fungi. It may be a treatment option for people who have not had success with other antifungal treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT04470024RecruitingPhase 1
Testing a vaccine plus immunotherapy for recurrent head and neck cancer
This early-phase (Phase 1b) study tests a vaccine designed to train the immune system to fight head and neck squamous cell carcinoma, plus standard immunotherapy. It may help some people by boosting the body’s anti-cancer immune response, but it mainly focuses on safety and finding the best approach.
Portland, OregonAges 18 years+ - NCT06731218RecruitingPhase 1
A study on RGB-5088 for type 1 diabetes
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT05970016RecruitingPhase 1/Phase 2
Study for advanced solid cancers with a DNA repair target
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Beijing, Beijing MunicipalityAges 18–70 - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+ - NCT05102747Recruiting
Surgery-like brain radiation for up to 5 metastases
This trial compares two ways of giving focused radiation to the brain for people with a limited number of brain metastases. It aims to see which schedule works best (and is likely best for costs and quality of life).
BordeauxAges 18 years+ - NCT07428499RecruitingPhase 3
Long-term safety of ADX-324 for hereditary angioedema
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
Litchfield Park, ArizonaAges 18 years+ - NCT06541847RecruitingPhase 2
Testing HLX-1502 for NF1 with Plexiform Neurofibromas
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Birmingham, AlabamaAges 12 years+ - NCT07061574RecruitingPhase 1/Phase 2
Low-dose ATG with Adalimumab or Verapamil for new type 1 diabetes
This study tests if giving a low dose of an immune-suppressing drug (ATG) followed by either adalimumab or verapamil can help preserve insulin production in people recently diagnosed with type 1 diabetes. You may qualify if you are 9 to 20 years old, have had type 1 diabetes for less than 6 months, and have some natural insulin left.
San Francisco, CaliforniaAges 9–20 - NCT06083883RecruitingPhase 1
NK cell therapy targeting NY-ESO-1 for sarcomas
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
Houston, TexasAges 16–80 - NCT07259538RecruitingPhase 1
Safety study of VVN432 nasal spray
This trial tests a nasal spray called VVN432 in healthy volunteers and people with chronic sinusitis. It checks if the spray is safe and how the body processes it.
BeijingAges 18–55 - NCT06735820RecruitingPhase 1/Phase 2
MEK and MDM2 inhibitors for NF1-related tumors
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06526923RecruitingPhase 1/Phase 2
Testing SP-101 gene therapy for cystic fibrosis
This trial tests a new gene therapy called SP-101 for cystic fibrosis. It aims to see if SP-101 is safe and effective for improving lung function.
Kansas City, KansasAges 18–65 - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Phoenix, ArizonaAges 1 month–21 years - NCT07418736RecruitingPhase 2
CM326 for moderate to severe COPD
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Beijing, Beijing MunicipalityAges 40–85 - NCT06942520RecruitingPhase 2
Gene therapy for diabetic macular edema in adults
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
Reno, NevadaAges 25–89 - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT02402660Enrolling by invitationPhase 2
Test ALK-001 for Stargardt disease eye changes and comfort
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
Phoenix, ArizonaAges 8–70 - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT06564584RecruitingPhase 2
Study of TLC-2716 for high triglycerides and fatty liver disease
This trial tests an investigational drug called TLC-2716 for people with very high triglycerides and a type of fatty liver disease (NAFLD or NASH). The goal is to see if it is safe and can help lower fat levels in the blood and liver.
Guadalajara, JaliscoAges 18–70 - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT01297400RecruitingPhase 2
Testing a topical treatment for thermal burns
This trial studies whether a topical medicine (MW-III) is safe and helps heal thermal burns. It is for adults with relatively limited burn size and certain burn depths, while excluding infected or high-risk wounds.
Phoenix, ArizonaAges 18 years+
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 1?
- Yes. Clin2 currently lists 285 recruiting phase 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.